Pharmacoeconomic analysis of epidermal growth factor (HeberprotP ®) for the treatment of diabetic foot ulcers

Cover Page


Introduction. The epidermal growth factor (EGF; HeberprotP ®) is the new treatment for deep persistent diabetic foot ulcers (Wagner grade 3–4). The effectiveness of EGF measured as the reduction of the time to complete granulation of tissue lesions was confirmed in randomised clinical trials, but the cost of this new treatment is high. Aim. To analyze the costs and outcomes of the use of EGF (Heberprot-P®) for the treatment of DFU in high- ly specialized medical institutions. Material and methods. We tested the hypothesis that the use of Heberprot-P® in diabetic foot ulcers – DFU – (Wagner grade 3–4) would reduce the rate of amputations and increase survival at acceptable cost for the Russian healthcare system. We used the data from international published literature to construct mathematical model representing clinical outcomes in the cohort of patients treated with only standard methods or standard methods in combination with Heberport-P®. We calculated direct costs associated with both strategies of treatment taking into account the risk of amputation. Results. The use of Heberprot-P® may prevent 52 amputations and save 29.54 years of life in a cohort of 100 DFU patients (Wagner grade 3–4). The incremental costs of EGF treatment were RUR 1.170.000 per life year gained and did not exceed the accepted threshold of less than three times GDP per capita. Conclusion. Mathematic modelling demonstrated the feasibility of introduction of EGF in combination with standard treatment for DFU in highly specialized medical institutions.

About the authors

G R Galstyan

doktor med. nauk, professor, zav. otdeleniem “diabeticheskaya stopa” FGBU ENTs

V I Ignatieva

menedzher Natsional'nogo tsentra po otsenke tekhnologiy zdravookhraneniya

M V Avksentieva

professor kafedry obshchestvennogo zdravookhraneniya i profilakticheskoy meditsiny Pervogo MGMU im. I.M. Sechenova

I I Dedov

akademik RAN i RAMN, direktor FGBU ENTs, prezident RAMN


  1. Дедов И.И., Шестакова М.В., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (5-й выпуск). Сахарный диабет. 2011;(3s):2-72. doi: 10.14341/2072-0351-5612
  2. Reiber G.E. The epidemiology of diabetic foot problems. Diabet Med. 1996; 13 (suppl. 1): S6–S11.
  3. Singh N., Armstrong D.G., Lipsky B.A. Preventing foot ulcers in patients with diabetes. JAMA. 2005; 293: 217–228.
  4. Reiber G.E. Epidemiology of foot ulcers and amputations in the diabetic foot. In: Bowker J.H., Pfeifer M.A., eds. The Diabetic Foot. St Louis, Mo: Mosby; 2001: 13–32.
  5. Siitonen O.I., Niskanen L.K., Laakso M. et al. Lowerextremi ty amputations in diabetic and nondiabetic patients: a popu lationbased study in eastern Finland. Diabetes Care. 1993; 1616–1620.
  6. Trautner C., Haastert B., Giani G., Berger M. Incidence of lower limb amputations and diabetes. Diabetes Care. 1996; 191006–191009.
  7. Lavery L.A., Armstrong D.G., Wunderlich R.P. et al. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and nonHispanic whites from a diabetes disease management cohort. Diabetes Care. 2003; 261435–261438.
  8. Armstrong D.G., Lavery L.A., Quebedeaux T.L., Walker S.C. Surgical morbidity and the risk of amputation due to infected puncture wounds in diabetic versus nondiabetic adults. South Med. J. 1997; 90384–90389.
  9. World Health Organization WHO. World Diabetes Day: too many people are losing lower limbs unnecessarily to diabetes.
  10. Stockl K., Vanderpalas A., Tafesse E. et al. Costs of lower extremity ulcers among patients with diabetes. Diabetes Care. 2004; 27: 21-29.
  11. Holzer S.E., Camerota A., Martens L. et al. Costs and dura tion of care for lower extremity ulcers in patients with dia betes. Clin. Ther. 1998; 20:1-69.
  12. Acosta J.B., Savigne W., Valdez C. et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int. Wound J. 2006; 3 (3): 232–239.
  13. FernandezMontequin J.I., InfanteCristia E., Valenzuela Silva C. et al. Intralesional injections of CitoprotP (recombi nant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int. Wound J. 2007; 4 (4): 333–343.
  14. Fernandez Montequin J.I., Betancourt B.Y., Leyva Gonzalez G. et al. Intralesional administration of epidermal growth factorbased formulation (HeberprotP) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int. Wound J. 2009; 6 (1): 67–72.
  15. Fernandez Montequin J.I., Valenzuela Silva C.M., Diaz O.G. et al. Intralesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, doubleblind study. Int. Wound J. 2009; 6 (6): 432–443.
  16. Garcia Herrera C.M.A.L., Rodriguez Fernandez R., Ruiz V.M. rd et al. Reduction in the amputation rate with Heberprot P in the local treatment of diabetic foot. Spanish Journal of Surgical Research. 2011; XIV (1): 21–26.
  17. Larsson J., Agardh C.D., Apelqvist J., Stenstrom A. Long term prognosis after healed amputation in patients with dia betes. Clin. Orthop. Relat. Res. 1998; 350: 149–158.
  18. FernandezMontequin J.I., ValenzuelaSilva C.M., Diaz O.G. et al. Intralesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebocontrolled, doubleblind study. Int. Wound J. 2009; 6 (6): 432–443.
  19. Faglia E., Favales F., Morabito A. New ulceration, new major amputation, and survival rates in diabetic subjects hospitalized for foot ulceration from 1990 to 1993: a 6.5year follow up. Diabetes Care. 2001; 24: 78–83.
  20. Утвержденная стоимость территориальной программы государственных гарантий оказания гражданам Российской Федерации бесплатной медицинской помощи по источникам ее финансового обеспечения на 2012 год, город Москва.
  21. Доброквашин С.В., Якупов Р.Р. Опыт хирургического лечения синдрома диабетической стопы. Каз. мед. ж. 2010;5.
  22. Цены на технические средства реабилитации по контрактам региональных отделений Фонда социального страхования Российской Федерации.
  23. Постановление Правительства г. Москвы от 24.02.2010 № 163пп “Об установлении торговых надбавок к ценам на лекарственные средства”.
  24. Global status report on noncommunicable diseases 2010. Description of the global burden of NCDs, their risk factors and determinants.
  25. Приказ Министерства здравоохранения и социального развития Российской Федерации от 28 декабря 2011 г. № 1689н “Об утверждении порядка направления граждан Российской Федерации для оказания высокотехнологичной медицинской помощи за счет бюджетных ассигнований, предусмотренных в федеральном бюджете Министерству здравоохранения и социального развития Российской Федерации, с применением специализированной информационной системы”.
  26. Tentolouris N., AlSabbagh S., Walker M.G. et al. Mortality in diabetic and nondiabetic patients after amputations performed from 1990 to 1995: a 5year follow-up study. Diabetes Care. 2004; 27 (7): 1598–1604.
  27. Риффель А.В. Избранные вопросы социальной геронтологии: правовой и медицинский аспекты. М.: “Академия естествознания”, 2009. 762.
  28. Павлова М.Г., Гусов Т.В., Лаврищева Н.В. Синдром диабетической стопы. Трудный пациент. 2006; 1: 49–54.



Abstract - 2027

PDF (Russian) - 598



Copyright (c) 2013 ., ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies